Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1CNS 1

Conditions

Sarcoma 1Neuroblastoma 1Lymphoma 1Leukemia 1Central Nervous System Neoplasms 1

Interventions

Cyclophosphamide 9Melphalan 8X-Rays 7Specimen Handling 7Phantoms, Imaging 7Magnetic Resonance Spectroscopy 7Busulfan 7Flow Cytometry 6Filgrastim 6Nuclear Medicine Department, Hospital 5Methylprednisolone 5Carboplatin 5Biopsy 5Therapeutics 4Radiotherapy 4Psychiatric Rehabilitation 4Ipilimumab 4Etoposide 4Antilymphocyte Serum 4Alemtuzumab 4fludarabine 3Topotecan 3Thiotepa 3Stem Cell Transplantation 3Polymerase Chain Reaction 3Peripheral Blood Stem Cell Transplantation 3Nivolumab 3Immunologic Techniques 3Crizotinib 3Caspofungin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroblastoma × Fenofibrate × Lymphoid × Clear all
NCT00357500 2014-10-01

Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer

Dana-Farber Cancer Institute

Phase 2 Completed
101 enrolled 10 charts
CNSLymphoidOther hematologic neoplasmSarcoma

Leukemia, Lymphoma, Neuroblastoma, Sarcoma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡